X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs SUN PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES SUN PHARMA PIRAMAL ENTERPRISES/
SUN PHARMA
 
P/E (TTM) x 9.4 28.0 33.6% View Chart
P/BV x 1.7 2.9 58.2% View Chart
Dividend Yield % 1.0 0.4 221.7%  

Financials

 PIRAMAL ENTERPRISES   SUN PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
SUN PHARMA
Mar-18
PIRAMAL ENTERPRISES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,083701 440.1%   
Low Rs1,902433 439.1%   
Sales per share (Unadj.) Rs589.7110.4 534.1%  
Earnings per share (Unadj.) Rs284.011.0 2,587.4%  
Cash flow per share (Unadj.) Rs310.517.2 1,802.3%  
Dividends per share (Unadj.) Rs25.002.00 1,250.0%  
Dividend yield (eoy) %1.00.4 284.3%  
Book value per share (Unadj.) Rs1,467.0158.8 923.8%  
Shares outstanding (eoy) m180.272,399.26 7.5%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x4.25.1 82.3%   
Avg P/E ratio x8.851.6 17.0%  
P/CF ratio (eoy) x8.032.9 24.4%  
Price / Book Value ratio x1.73.6 47.6%  
Dividend payout %8.818.2 48.3%   
Avg Mkt Cap Rs m449,3321,360,021 33.0%   
No. of employees `0006.817.8 38.5%   
Total wages/salary Rs m19,88153,671 37.0%   
Avg. sales/employee Rs Th15,535.614,890.9 104.3%   
Avg. wages/employee Rs Th2,905.43,017.1 96.3%   
Avg. net profit/employee Rs Th7,482.51,480.6 505.4%   
INCOME DATA
Net Sales Rs m106,310264,895 40.1%  
Other income Rs m2,5958,388 30.9%   
Total revenues Rs m108,906273,282 39.9%   
Gross profit Rs m51,59956,081 92.0%  
Depreciation Rs m4,77314,998 31.8%   
Interest Rs m29,7835,176 575.4%   
Profit before tax Rs m19,63844,295 44.3%   
Minority Interest Rs m2,8010-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m-28,7648,452 -340.3%   
Profit after tax Rs m51,20326,338 194.4%  
Gross profit margin %48.521.2 229.3%  
Effective tax rate %-146.519.1 -767.6%   
Net profit margin %48.29.9 484.4%  
BALANCE SHEET DATA
Current assets Rs m118,154316,359 37.3%   
Current liabilities Rs m462,260198,643 232.7%   
Net working cap to sales %-323.744.4 -728.4%  
Current ratio x0.31.6 16.0%  
Inventory Days Days2795 28.0%  
Debtors Days Days47108 43.2%  
Net fixed assets Rs m113,727213,178 53.3%   
Share capital Rs m3612,399 15.0%   
"Free" reserves Rs m264,093378,606 69.8%   
Net worth Rs m264,454381,006 69.4%   
Long term debt Rs m242,20617,721 1,366.8%   
Total assets Rs m726,834643,028 113.0%  
Interest coverage x1.79.6 17.4%   
Debt to equity ratio x0.90 1,969.2%  
Sales to assets ratio x0.10.4 35.5%   
Return on assets %11.14.9 227.4%  
Return on equity %19.46.9 280.1%  
Return on capital %10.310.0 102.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,11040,816 37.0%   
Fx outflow Rs m4,29830,143 14.3%   
Net fx Rs m10,81310,673 101.3%   
CASH FLOW
From Operations Rs m-159,66639,072 -408.7%  
From Investments Rs m-17,677-33,708 52.4%  
From Financial Activity Rs m186,503-15,393 -1,211.6%  
Net Cashflow Rs m9,364-7,359 -127.2%  

Share Holding

Indian Promoters % 52.9 63.7 83.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 5.1 78.0%  
FIIs % 26.6 23.0 115.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 8.3 198.8%  
Shareholders   93,274 133,026 70.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   VENUS REMEDIES  MERCK  GSK PHARMA  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Uptrend, Jet Airways in Focus and Other Top Stocks in Action Today(Pre-Open)

On Monday, share markets in India opened on a positive note and ended the day in green after a volatile day of trading.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY19); Net Profit Up 21.8% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 21.8% YoY). Sales on the other hand came in at Rs 35 bn (up 22.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Mar 18, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS